Comparative Evaluation of Different Brands of Loratadine Tablets Marketed in Addis Ababa, Ethiopia

DOI:

https://doi.org/10.37285/ijpsn.2019.12.4.3

Authors

  • Abrham Temesgen
  • Yohannis Eshetu
  • Muluken Nigatu

Abstract

The impact of counterfeit and substandard medicines has been increasing and becoming a public health problem as it significantly increases mortality and morbidity in low income countries. Loratadine is among the drug classes which are most falsified worldwide and is a frequently prescribed anti-allergy medication. As Ethiopia is one of the low-income countries and depends mostly on imported pharmaceutical products, it is necessary to evaluate the quality of drug products being marketed. This study was conducted with the objective of evaluating and comparing the quality of different brands of loratadine 10 mg tablets collected from pharmacy outlets in Addis Ababa city. Tablets were evaluated for weight variation, thickness, hardness, friability, disintegration time and in vitro drug release. All products complied with the pharmacopeial specifications for weight variation and friability. With regard to disintegration time, all sample products disintegrate in less than 15 min as per the pharmacopeial requirement except one product (product E) which is out of the pharmacopeial specification. Dissolution test showed that all the tested products released more than 80% of drug content within 60 min which is in agreement with the pharmacopeial specification.  

 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Loratadine, comparative study, in vitro evaluation, antihistamine

Downloads

Published

2019-07-31

How to Cite

1.
Temesgen A, Eshetu Y, Nigatu M. Comparative Evaluation of Different Brands of Loratadine Tablets Marketed in Addis Ababa, Ethiopia. Scopus Indexed [Internet]. 2019 Jul. 31 [cited 2024 Dec. 22];12(4):4580-4. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/306

Issue

Section

Research Articles

References

Adetunji OA, Adigun NF and Odeniyi MA (2015). Pharmaceutical equivalent studies of some commercially available brands of Loratadine hydrochloride tablets. African Journal of Medicine and Medical Science 44: 269-276.
Ansel HC and Allen LV (1995). Pharmaceutical dosage forms and drug delivery systems, 6th edn, Williams and Wilkins, USA, pp 55-98.
Brevedan V, Varillas M and Vidal NG (2011): Stability of loratadine tablets in Argentina. Latin American Journal of Pharmacy 30: 696-701.
Christian L, Collins L, Kiatgrajai M, Merle A, Mukherji N and Quade A (2012). The Problem of Substandard Medicines in Developing Countries. 84: e1-71, Available at: https://www.lafollete.wisc.edu.
Diaz DA, Colgan ST, Langer CS, Bandi NT, Likar MD and Alstine LV (2016). Dissolution Similarity Requirements: How Similar or Dissimilar are the Global Regulatory Expectations? The AAPS Journal 18: 15-22.
Getie M and Gebre-Mariam T (1998). In vitro comparative evaluation of some tablets available in drug retail outlet of Addis Ababa: Physical properties, content uniformity and dissolution profiles. Ethiopian Pharmaceutical Journal 16: 12-24.
Huque S, et al. (2017). Comparative in vitro equivalence evaluation of some Desloratadine generic tablets marketed in Bangladesh. International Journal of Applied Research 3: 288-293.
Mohamed AAH (2015). Comparative Study of Physicochemical Properties of Loratadine Tablets (10 mg) in Retail Outlets in Khartoum City, Sudan. International Journal of Food, Nutrition and Public Health 7: 101-110.
Motola C (2009). H1-antihistamine in allergic disease. Current Allergy & Clinical Immunology 22: 71-74.
Oishi TM, Munna S, Noor Z, Das S, Akhter R, Huque S and Shahriar M (2017). Comparative In Vitro Equivalence Evaluation of Some Loratadine Generic Tablets Marketed in Bangladesh. IOSR Journal of Pharmacy and Biological Sciences 12: 76-81.
Sprawls JB (1974). Sprawl’s American Pharmacy: An introduction to pharmaceutical techniques and dosage forms, 7th edn, Lipincott Williams, USA, pp 374-385.
United States Pharmacopoeia/National Formulary (USP36/NF31) (2013). The United States Pharmacopoeial Convention; Electronic copy, Section A3.
Wang J, Wu J and Lai H (2015). Allergic Disease Epidemiology. In: Tao A and Raz E eds, Allergy Bioinformatics, edn, Springer, p 15-35.
Williams L and McKnight E (2014). The Real Impact of Counterfeit Medications: Generic Drug Review supply, affordable medicine, US Pharm, 39: 44-46.